COVID-19 Antiviral Treatment

In January, Health Canada approved a new pill-form COVID-19 antiviral drug called Paxlovid. A very limited supply of the new drug is available and Ontario Health is prioritizing its use in COVID-positive individuals most at-risk of severe outcomes including:

  • immunocompromised individuals (PDF) aged 18 and over regardless of vaccine status
  • unvaccinated individuals aged 60 and over
  • unvaccinated First Nation, Inuit and Métis individuals aged 50 and over
  • unvaccinated individuals aged 50 and over with one or more risk factors (PDF)

Who to contact if you think you’re eligible

Due to the extremely limited supply, Paxlovid is currently only offered in consultation with your family doctor or pharmacy. Paxlovid does not replace the COVID-19 vaccines, but a treatment for those who are COVID-positive, confirmed through a PCR test, and who meet the eligibility criteria listed above. If you think you may be eligible to receive Paxlovid, you can:

If you are experiencing moderate COVID-19 symptoms and require care:

  • For PCR COVID testing:
  • For (Antiviral therapies (Paxlovid/Remdesivir) please contact your family doctor or pharmacy
  • For other Cold, Flu and COVID care please contact your family doctor and pharmacy
  • A full list of alternative care options is available here
  • Connect to care 24/7 with Health 811

If you are experiencing severe symptoms, please call 911 or visit your nearest Emergency Department.


Primary care providers, pharmacies and Health 811 can refer a patient for an assessment to determine eligibility for Paxlovid. Referrals must be made through your family doctor or pharmacy.

Referral Form for Primary Care Providers: Referral for Nirmatrelvir / Ritonavir (Paxlovid®)